drugset / Trial / NCT00203021
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis (RRMS). Participants have scheduled visits every 3 months to assess glatiramer acetate safety and their Multiple Sclerosis (MS) status.
Timeline
- Start
- 1994-03-26
- Primary completion
- 2018-02-28
- Completion
- 2018-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glatiramer Acetate | Small molecule | 20 mg | Subcutaneous |
| Subject | Glatiramer Acetate | Small molecule | 40 mg | Subcutaneous |